Skip to content

Single center randomized controlled study for effects of probiotics on small intestinal bacterial overgrowth and intestinal permeability in patients with chronic liver disease.

probiotics on small intestinal bacterial overgrowth and intestinal permeability in patients with chronic liver disease.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CRIS
Registry ID
KCT0000081
Enrollment
125
Registered
2011-01-20
Start date
2010-12-30
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : probiotics DP 2Capsule 4week

Sponsors

Hanyang University Seoul Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Men and women under the age of 18-65 2.Chronic liver disease(Cirrhosis and Alcoholic liver disease) 3.In the control group and no history of ingestion of alcohol liver disease among patients who visited a medical examination and colonic microflora jangtugwado agreed to test the patients 4. Pregnant women or surgical diagnosis bulimin (urine or-hCG) results were negative women of childbearing age. Appropriate method of contraception during the trial (for example, oral contraceptives, IUD, double contraception (double-barrier method) or hormone transplants) during the test period through the "unlikely to become pregnant" man / woman or this agreement 5.This experiment agrees in writing to the patient.

Exclusion criteria

Exclusion criteria: 1.Probiotics nots sensitization to drug preparations 2.Pregnant or lactating women 3.Severe congestive heart failure,or a person with severe angina 4.the last 2 weeks in those who underwent colonoscopy and colon cleansing 5.Promoter within 2 weeks of gastrointestinal,gastric inhibitor(PPI,H2 blocker)is used 6.Dulpalrakui within two weeks of use is limited to patients without the need to use dulpalrak. 7.Lactose Intolerance, or if the immune suppressed patients diagnosed with 8.This can have an impact on drug tests medications are taking or have taken a patient during the study period.Only if the patient is taking medication,a week to go through the withdrawal groups can participate in testing. 9.160mmHg systolic blood pressure measured at visit 1 or diastolic blood pressure exceeded 100mmHg,regardless of whether treatment of hypertension medication does not control. 10.Uncontrolled endocrine disease(dangnyodeung),metabolic diseases(two of secondary hyperlipidemia)or patients with thyroid dysfunctic(hypothyroidism,subjects with a history of at least four weeks before the visit a reliable receiving thyroid hormone replacement therapy If you have,TSH levels measured at two visits within the normal range only if there is,can participate in this test.) 11.In visiting a compromised renal function or(creatinine>2.0mg/dL)nephrotic syndrome observed in 12.When expressed in the cancer within the past five years(except in the case turned out to be cured) 13.Within the past five years,mentally unstable,and drug/alcohol abuse or a history of major psychiatric disorders are not adequately controlled by medication if it is not stable 14.Within 3months of a previous visit to the spirit of taking care when solvent 15.Visit a previous systemic corticosteroids within 1month of taking the case 16.Appendectomy and hernia surgery, patients who underwent abdominal surgery other than 17.Other clinical judgments of patients who are judged unsuitable for

Design outcomes

Primary

MeasureTime frame
intestinal permeability

Secondary

MeasureTime frame
Small bowel bacterial overgrowth;Bowel flora

Countries

Korea, Republic of

Contacts

Public ContactDaewon Jun

Hanyang University Seoul Hospital

@

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026